Nevro (NYSE:NVRO) announced today that UnitedHealthcare will provide coverage for its painful diabetic neuropathy (PDN) treatment.
Redwood City, California-based Nevro’s Senza 10 kHz spinal cord stimulation (SCS) therapy will now be covered by the largest private health insurance company in the U.S. for dates of service on or after March 1, 2022, according to a news release.
Under the policy, UnitedHealthcare considers Nevro’s high-frequency SCS system to be proven and medically necessary for the treatment of diabetic neuropathy when specified criteria are met.
Senza received FDA approval for treating chronic pain associated with PDN in July 2021. The company said at the time that Senza is the only spinal cord stimulation system approved by the FDA with a specific indication for treating PDN.
“We believe this expeditious coverage decision from UnitedHealthcare following our submission to their medical policy team late last year is a major milestone and will facilitate access to Nevro’s proprietary 10 kHz therapy for PDN patients,” Nevro Chairman, CEO & President D. Keith Grossman said in the release. “As the only spinal cord stimulation system that is FDA approved to treat PDN, we believe we are uniquely positioned to treat the thousands of patients suffering from the debilitating effects of PDN with a proven non-drug option.
“We also believe our strong and growing body of published, peer-reviewed clinical and real-world data will be the basis for further coverage decisions by other major health plans in 2022 and beyond.”